NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnostics Assessment Programme

Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10)

Stakeholder list

Manufacturer(s)

Agendia NV

Genomic Health UK

Myriad Genetics

Nanostring Technologies

Royal Marsden Hospital Trust

Manufacturer(s) of related technologies (not included in scope)

OncoMark Ltd

Roche Diagnostics

Professional groups

Association of Breast Surgery

CM-PATH (Cellular and Molecular Pathology Initiative)

Royal College of Pathologists

Royal College of Physicians

Royal College of Radiologists

The London Breast Clinic

UK Breast Cancer Group (UKBCG)

Patient/carer groups

Breast Cancer Now

Cancer Research UK

Statutory organisation

Public Health England

Research groups

Peony Breast Cancer Unit

A provider of NHS services in England

Colchester Hospital NHS Foundation Trust

A commissioner of NHS services in England

Greater Manchester Cancer / NHS Trafford CCG

Associated guideline groups

None

External Assessment Group

School of Health and Related Research (ScHARR), The University of Sheffield

Others

Cancer and Society in the 21st Century research team, Centre for Population Health Sciences, The University of Edinburgh

Decision Resources Group Abacus

Department of Health

Healthcare Improvement Scotland

Medicines & Healthcare products Regulatory Agency

NHS England

Welsh Government

Definitions:

Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).